WIRE — Current evidence applies only to carefully selected men with low-risk, localised prostate cancer who are under active surveillance and have clinically confirmed testosterone deficiency.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.